Defucosylated Anti–CC Chemokine Receptor 4 Monoclonal Antibody Combined with Immunomodulatory Cytokines: A Novel Immunotherapy for Aggressive/Refractory Mycosis Fungoides and Sézary Syndrome
Open Access
- 1 November 2007
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 13 (21), 6494-6500
- https://doi.org/10.1158/1078-0432.ccr-07-1324
Abstract
Purpose: Sézary syndrome (SS) and Mycosis fungoides (MF) in the advanced stage have dismal prognoses. Because CC chemokine receptor 4 (CCR4) has an important role in the skin-homing capacity of MF/SS cells, we postulated that anti-CCR4 monoclonal antibody (mAb) could represent a novel therapeutic agent against aggressive/refractory MF/SS. Experimental Design: The defucosylated next-generation therapeutic mAb KM2760 induces enhanced antibody-dependent cellular cytotoxicity (ADCC). Here, we assessed the therapeutic potential of this antibody against aggressive MF/SS tumor cells in vitro and in animal models in vivo. Results: KM2760 induced robust ADCC by peripheral blood mononuclear cell (PBMC) from healthy controls against a MF/SS cell line as well as against primary tumor cells from patients with aggressive MF/SS. KM2760 also showed significant antitumor activity in disseminated and nondisseminated MF/SS mouse models. In addition, ∼30% of autologous MF/SS tumor cells were killed in in vitro assays of KM2760-induced ADCC mediated by patients' PBMC after only 4 h, despite the low numbers of natural killer cells present in these PBMCs. It is also shown that ADCC induced by defucosylated therapeutic mAb can be greatly augmented by the immunomodulatory cytokines interleukin-12, IFN-α-2b, and IFN-γ. Conclusions: The present study has encouraged us in the conducting of a phase I clinical trial of a completely defucosylated anti-CCR4 mAb in patients with CCR4-positive T-cell lymphomas, including aggressive MF/SS (ClinicalTrials.gov identifier: NCT00355472). In the near future, the efficacy not only of defucosylated anti-CCR4 mAb single-agent treatment but also of combination therapy with immunomodulatory cytokines will be clinically established to target aggressive/refractory MF/SS.Keywords
This publication has 40 references indexed in Scilit:
- The CCR4 as a novel-specific molecular target for immunotherapy in Hodgkin lymphomaLeukemia, 2006
- CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor–β–dependent mannerThe Journal of Experimental Medicine, 2005
- Enhanced Natural Killer Cell Binding and Activation by Low-Fucose IgG1 Antibody Results in Potent Antibody-Dependent Cellular Cytotoxicity Induction at Lower Antigen DensityClinical Cancer Research, 2005
- CXC Chemokine Receptor 3 and CC Chemokine Receptor 4 Expression in T-Cell and NK-Cell Lymphomas with Special Reference to Clinicopathological Significance for Peripheral T-Cell Lymphoma, UnspecifiedClinical Cancer Research, 2004
- A modified staging classification for cutaneous T-cell lymphomaJournal of the American Academy of Dermatology, 2001
- Establishment of an IL-2 independent, human T-cell line possessing only the p70 IL-2 receptorInternational Journal of Cancer, 1991
- Depressed lymphokine activated killer cell activity in mycosis fungoides. A possible marker for aggressive diseaseArchives of Dermatology, 1990
- Isolation and Transmission of Human Retrovirus (Human T-Cell Leukemia Virus)Science, 1983
- Decreased Natural-Killer-Cell Activity in Cutaneous T-Cell LymphomasNew England Journal of Medicine, 1983
- Human cutaneous T cell lymphoma and leukemia cell lines produce and respond to T cell growth factorThe Journal of Experimental Medicine, 1981